About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals.
To promote successful and lasting management of the TB epidemic, effective vaccination is required.
[2] The design incentive behind aerosol delivery is to target the lungs rapidly, easily and painlessly[9] in contrast to intradermal immunization.
[2] Research data suggests aerosol delivery has not only physiological and economic advantages,[9] but also the potential to supplement systemic vaccination.
[2] Treatment and prevention of TB has been delayed compared to the resources and research efforts put into other diseases.
[5] A 2013 study deemed zebrafish a potentially suitable model organism for preclinical vaccine development.